Anti-tumor necrosis factor-α monoclonal antibody alleviates parenteral nutrition-associated liver disease in mice

Journal of Parenteral and Enteral Nutrition

Volumn 36, Issue 2, 2012, Pages 219-225

  Li, Jing ^a   Gong, Yi Ming ^a   Wu, Jiang ^a   Wu, Wen Jie ^a   Cai, Wei ^a  

^a XINHUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

adenosine triphosphate binding cassette transporters; liver disease; parenteral nutrition; tumor necrosis factor

Indexed keywords

ABC TRANSPORTER; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; BILIRUBIN GLUCURONIDE; INFLIXIMAB; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CENTRAL VENOUS CATHETER; CENTRAL VENOUS CATHETERIZATION; CHOLESTASIS; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HISTOPATHOLOGY; LIVER DISEASE; MALE; MOUSE; NONHUMAN; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ATP-BINDING CASSETTE TRANSPORTERS; BILE ACIDS AND SALTS; BILIRUBIN; CHOLESTASIS; LIVER; LIVER DISEASES; MALE; MICE; MICE, INBRED C57BL; P-GLYCOPROTEINS; PARENTERAL NUTRITION; RANDOM ALLOCATION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

MUS;

EID: 84863229603     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607111424412     Document Type: Article

References (43)

1. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001 ; 11: 1156-1166 (Pubitemid 32677289)
2. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002 ; 71: 537-592 (Pubitemid 34800230)
3. Trauner M. Molecular alterations of canalicular transport systems in experimental models of cholestasis: possible functional correlations. Yale J Biol Med. 1997 ; 70: 365-378 (Pubitemid 28262252)
4. Muller M, Roelofsen H, Jansen PL. Secretion of organic anions by hepatocytes: involvement of homologues of the multidrug resistance protein. Semin Liver Dis. 1996 ; 16: 211-220 (Pubitemid 26177632)
5. Oude Elferink R, Meijer D, Kuipers F, Jansen PL, Groen AK, Groothuis GM. Hepatobiliary secretion of organic compounds: molecular mechanisms of membrane transport. Biochim Biophys Acta. 1995 ; 1241: 215-218
6. Balistreri W, Bezerra J, Jansen P, Karpen SJ, Shneider BL, Suchy FJ. Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference. Hepatology ; 2005 ; 2005. 222.
7. Trauner M, Wagner M, Fickert P, Zollner G. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. J Clin Gastroenterol. 2005 ; 39: S111 - S124 (Pubitemid 40397024)
8. Quigley EMM, Marsh MN, Shaffer JL, Markin RS. Hepatobiliary complications of total parenteral nutrition. Gastroenterology. 1993 ; 104: 286-301 (Pubitemid 23040035)
9. Btaiche IF, Khalidi N. Parenteral nutrition-associated liver complications in children. Pharmacotherapy. 2002 ; 22: 188-211 (Pubitemid 34112881)
10. Zheng YJ, Tam YK, Coutts RT. Endotoxin and cytokine released during parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004 ; 28: 163-168 (Pubitemid 38507246)
11. Gäbele E, Froh M, Arteel GE, et al. TNFα is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Commun. 2009 ; 378: 348-353
12. Forrest EH, Oien KA, Dickson S, Galloway D, Mills PR. Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha. Liver. 2002 ; 22: 317-320
13. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse human chimeric anti-TNF antibody. Mol Immunol. 1993 ; 30: 1443-1453
14. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNFα monoclonal antibody Ca2binds recombinant transmembrane TNFα and activates immune effector functions. Cytokine. 1995 ; 7: 251-259
15. Tazuke Y, Kiristioglu I, Heidelberger KP, Eisenbraun MD, Teitelbaum DH. Hepatic P-glycoprotein changes with total parenteral nutrition administration. JPEN J Parenter Enteral Nutr. 2004 ; 28: 1-6 (Pubitemid 38084579)
16. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008 ; 117: 244-279
17. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation. 2008 ; 31: 91-98
18. Barbuio R, Milanski M, Bertolo MB, Saad MJ, Velloso LA. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. J Endocrinol. 2007 ; 194: 539-550 (Pubitemid 47471222)
19. Bahcecioglu IH, Koca SS, Poyrazoglu OK, et al. Hepatoprotective effect of infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis. Inflammation. 2008 ; 31: 215-221
20. Pappo I, Bercovier H, Berry E, Gallilly R, Feigin E, Freund HR. Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. JPEN J Parenter Enteral Nutr. 1995 ; 19: 80-82
21. Loff S, Waag KL, Kranzlin B, et al. Long-term total parenteral nutrition induced hepatobiliary dysfunction in a rabbit model. J Pediatr Surg. 1998 ; 33: 694-699 (Pubitemid 28213208)
22. Wu J, Wang X, Cai W, Hong L, Tang Q. Bifidobacterium adolescentis supplementation ameliorates parenteral nutrition-induced liver injury in infant rabbits. Dig Dis Sci. 2010 ; 55: 2814-2820
23. Larionov A, Krause A, Miller W. A standard curve based method for relative real time PCR data processing. BMC Bioinformatics. 2005 ; 6: 62-77
24. Bemelmans MH, Gouma DJ, Greve JW, Buurman WA. Cytokines tumor necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology. 1992 ; 15: 1132-1136
25. Yoshioka K, Kakumu S, Arao M, et al. Immunohistochemical studies of intrahepatic tumor necrosis factor in chronic liver disease. J Clin Pathol. 1990 ; 43: 298-302 (Pubitemid 20111780)
26. Fox ES, Kim JC, Tracy TF. NF-kappa B activation and modulation in hepatic macrophages during cholestatic injury. J Surg Res. 1997 ; 72: 129-134 (Pubitemid 27495583)
27. Whiting JF, Green RM, Rosenbluth AB, Gollan JL. Tumor necrosis factor-alpha decreases hepatocyte bile salt uptake and mediates endotoxin-induced cholestasis. Hepatology. 1995 ; 22: 1273-1278
28. Padillo FJ, Cruz A, Segura-Jiménez I, et al. Anti-TNF-alpha treatment and bile duct drainage restore cellular immunity and prevent tissue injury in experimental obstructive jaundice. Int J Immunopathol Pharmacol. 2007 ; 20: 855-860
29. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002 ; 2: 364-371 (Pubitemid 37328759)
30. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004 ; 36: 342-347 (Pubitemid 41115465)
31. Sands B, Blank M, Diamond R, Barrett J, van Deventer S. Maintenance infliximab does not result in increased abscess development in fitulizing Crohn's disease: results from the ACCENT II study. Aliment Pharmacol Ther. 2006 ; 23: 1127-1136 (Pubitemid 43779352)
32. O'Donnell S, Murphy S, Anwar MM, et al. Safety of infliximab in 10 years of clinical practice. Eur J Gastroenterol Hepatol. 2011 ; 23: 603-606
33. Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Dig Liver Dis. 2008 ; 40: S236 - S246 (Pubitemid 351878066)
34. Flendrie M, Creemers MC, Welsing PM, van Riel PL. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis: A longitudinal observational study. Rheumatol (Oxf). 2005 ; 44: 472-478 (Pubitemid 41511137)
35. Imaizumi K, Sugishita M, Usui M, Kawabe T, Hashimoto N, Hasegawa Y. Pulmonary infectious complications associated with anti-TNF alpha therapy (infliximab) for rheumatoid arthritis. Intern Med. 2006 ; 45: 685-688 (Pubitemid 43905483)
36. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009 ; 30: 253-264
37. Colomb V, Goulet O, Rambaud C, De Potter S, Sadoun E, BenHariz M. Long term parenteral nutrition (PN) in children: liver and gallbladder disease. Transplant Proc. 1992 ; 24: 1045-1055
38. Moseley RH. Sepsis-associated cholestasis. Gastroenterology. 1997 ; 112: 302-305
39. Reimund JM, Arondel Y, Finck G, Zimmermann F, Duclos B, Baumann R. Catheter-related infection in patients on home parenteral nutrition: results of a prospective survey. Clin Nutr. 2002 ; 21: 33-38 (Pubitemid 34257509)
40. Santarpia L, Alfonsi L, Tiseo D, et al. Central venous catheter infections and antibiotic therapy during long-term home parenteral nutrition: An 11-year follow-up study. JPEN J Parenter Enteral Nutr. 2010 ; 34: 254-262
41. Shou J, Lappin J, Minnard EA, Daly JM. Total parenteral nutrition, bacterial translocation, and host immune function. Am J Surg. 1994 ; 167: 145-150 (Pubitemid 24264156)
42. Okada Y, Klein NJ, van Saene HK, Webb G, Holzel H, Pierro A. Bactericidal activity against coagulase-negative staphylococci is impaired in infants receiving long-term parenteral nutrition. Ann Surg. 2000 ; 231: 276-281 (Pubitemid 30078812)
43. Xu D, Lu Q, Deitch EA. Elemental diet-induced bacterial translocation associated with systemic and intestinal immune suppression. JPEN J Parenter Enteral Nutr. 1998 ; 22: 37-41 (Pubitemid 28028587)